AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11081529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 11081529 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-positive individuals
Number of subjects: 233
Study 11081529 — intervention group
Group type: COMPARATOR
Intervention: HIV-1-negative individuals
Number of subjects: 233
Study 11081529 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-positive individuals with a history of HIV-1-related symptoms
Number of subjects: 233
Study 9172054 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma alkaline phosphatase (AP) in the highest quartile at 26 weeks
Number of subjects: 580
Study 9172054 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in plasma alkaline phosphatase (AP) from 19 to 26 weeks (highest quartile)
Number of subjects: 580
Study 9172054 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean birthweight (BWT) for highest quartile of increase in AP
Number of subjects: 580
Study 9172054 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean gestational age (GA) for highest quartile of increase in AP
Number of subjects: 580
Study 9172054 — intervention group
Group type: EXPERIMENTAL
Intervention: High AP at 26 weeks
Number of subjects: 580
Study 1588829 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d and 40 mg/d)
Number of subjects: 0
Study 1588829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (400 mg/d)
Number of subjects: 0
Study 3014473 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka-strain live varicella vaccine
Number of subjects: 30
Study 3014473 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate as an immunostimulant
Number of subjects: 30
Study 3014473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29224964 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of MMRV vaccine
Number of subjects: 5289
Study 29224964 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of combined MMR and one dose of monovalent varicella vaccine (MMR+V)
Number of subjects: 5289
Study 29224964 — intervention group
Group type: COMPARATOR
Intervention: Two doses of MMR vaccine (control)
Number of subjects: 5289
Study 29224964 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster cases
Number of subjects: 5289
Study 27061991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training three times a week for six weeks and counselling
Number of subjects: 40
Study 27061991 — intervention group
Group type: COMPARATOR
Intervention: Counselling only
Number of subjects: 40
Study 25439688 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection
Number of subjects: 4806
Study 25439688 — intervention group
Group type: COMPARATOR
Intervention: Axillary radiotherapy
Number of subjects: 4806
Study 22631672 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostar combined with chemoradiotherapy (CRT+E group)
Number of subjects: 52
Study 22631672 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy alone (CRT group)
Number of subjects: 52
Study 20808194 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver yoga (SY) exercise program, 3 times per week, 70 minutes per session, for 24 weeks
Number of subjects: 69
Study 20808194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 69
Study 18923351 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic microsurgery (TEM)
Number of subjects: 0
Study 16877146 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 U at preoperative days 14 and 7
Number of subjects: 50
Study 16877146 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 50
Study 12449158 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 50
Study 12449158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10738354 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting (2 VD, high costs)
Number of subjects: 1205
Study 10738354 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting (3 VD, high costs)
Number of subjects: 1205
Study 10738354 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting (2 VD, low costs)
Number of subjects: 1205
Study 10738354 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting (3 VD, low costs)
Number of subjects: 1205
Study 10738354 — intervention group
Group type: COMPARATOR
Intervention: CABG (high costs)
Number of subjects: 1205
Study 10738354 — intervention group
Group type: COMPARATOR
Intervention: CABG (low costs)
Number of subjects: 1205
Study 8787472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia
Number of subjects: 47
Study 8787472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 47
Study 8787472 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia
Number of subjects: 47
Study 2108474 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose pion irradiation (total doses from 2720-3420 cGy, fraction sizes from 170 to 205 cGy, treatment times from 4 to 5 weeks)
Number of subjects: 52
Study 2108474 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated treatment with 3280 cGy in 14-22 days
Number of subjects: 52
Study 2108474 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 52
Study 6107154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 38
Study 6107154 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (200 mg daily)
Number of subjects: 38
Study 6107154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 38
Study 6107154 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 38
Study 29542390 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (300 mg daily, 180 mg EPA and 120 mg DHA)
Number of subjects: 100
Study 29542390 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (200 IU daily)
Number of subjects: 100
Study 29542390 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E + Omega-3
Number of subjects: 100
Study 29542390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27440110 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg once daily
Number of subjects: 90
Study 27440110 — intervention group
Group type: COMPARATOR
Intervention: sitagliptin 100 mg once daily
Number of subjects: 90
Study 23764766 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical reduction (group 1, n=45)
Number of subjects: 88
Study 23764766 — intervention group
Group type: COMPARATOR
Intervention: Fusion in situ (group 2, n=43)
Number of subjects: 88
Study 22568428 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with 5‐fluorouracil
Number of subjects: 199
Study 22568428 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 199
Study 22568428 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with cataract surgery (Phaco/IOL)
Number of subjects: 199
Study 22568428 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with cataract surgery
Number of subjects: 199
Study 21400790 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists and hydroxyethyl starch solution (130/0.4)
Number of subjects: 0
Study 17626211 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental shaping procedure with monetary reward
Number of subjects: 22
Study 16215340 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% sucrose plus pacifier
Number of subjects: 66
Study 16215340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water plus pacifier
Number of subjects: 66
Study 16215340 — intervention group
Group type: COMPARATOR
Intervention: Standard care (positioning and swaddling)
Number of subjects: 66
Study 12054319 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered coping improvement-group intervention
Number of subjects: 201
Study 9745188 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 13
Study 7992066 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy plus carboplatin (60 to 70 mg/m2/d, days 1-5 and 29-33) with radiotherapy (5 x 2 Gy/wk to a dose of 50 Gy, continued to 70-74 Gy for inoperable patients)
Number of subjects: 178
Study 7992066 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated accelerated radiotherapy (2 x 1.6 Gy/d 5 days per week; total dose, 64 to 67.2 Gy) plus simultaneous intravenous carboplatin (60 mg/m2, days 1-5 and 29-33)
Number of subjects: 178
Study 7992066 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy plus carboplatin
Number of subjects: 178
Study 7992066 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated accelerated irradiation plus carboplatin
Number of subjects: 178
Study 2656068 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 12.5 cm H2O
Number of subjects: 10
Study 31928248 — intervention group
Group type: EXPERIMENTAL
Intervention: LOG model intervention implemented in 19 schools
Number of subjects: 157
Study 31928248 — intervention group
Group type: EXPERIMENTAL
Intervention: LOG model intervention
Number of subjects: 157
Study 31928248 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 schools)
Number of subjects: 157
Study 29948025 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 608
Study 29948025 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 608
Study 28821284 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week combined aerobic and resistance exercise program supervised by a physiotherapist, plus daily physical activity of at least 30 minutes
Number of subjects: 150
Study 28821284 — intervention group
Group type: COMPARATOR
Intervention: Usual care group maintaining habitual physical activity pattern
Number of subjects: 150
Study 25778445 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 0
Study 25778445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23232755 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 29
Study 23232755 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behaviour therapy
Number of subjects: 29
Study 22011360 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit
Number of subjects: 21
Study 22011360 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 21
Study 19433655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (n = 151)
Number of subjects: 301
Study 19433655 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (n = 150)
Number of subjects: 301
Study 16988496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 118
Study 16988496 — intervention group
Group type: COMPARATOR
Intervention: Omnivore diet
Number of subjects: 118
Study 16988496 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet
Number of subjects: 118
Study 16988496 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 118
Study 15269867 — intervention group
Group type: EXPERIMENTAL
Intervention: tinidazole‐dexamethasone‐iodoform paste
Number of subjects: 520
Study 15269867 — intervention group
Group type: COMPARATOR
Intervention: formocresol
Number of subjects: 520
Study 11095577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 41‐3290 (5, 10, and 30 mg)
Number of subjects: 30
Study 11095577 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 30
Study 11095577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9071224 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens fluorometry
Number of subjects: 79
Study 9071224 — intervention group
Group type: COMPARATOR
Intervention: Age alone
Number of subjects: 79
Study 8020525 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol-350 (350 mgI/ml)
Number of subjects: 120
Study 8020525 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol-400 (400 mgI/ml)
Number of subjects: 120
Study 8020525 — intervention group
Group type: COMPARATOR
Intervention: iopamidol-370 (370 mgI/ml)
Number of subjects: 120
Study 2690305 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin + early artificial rupture of the membranes
Number of subjects: 0
Study 2690305 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 vaginal gel (first dose: 1 mg, second dose 1 or 2 mg, six hours later)
Number of subjects: 0
Study 2690305 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 vaginal gel
Number of subjects: 0
Study 1135409 — intervention group
Group type: EXPERIMENTAL
Intervention: Atmospheric oxygen breathing during radiotherapy
Number of subjects: 0
Study 1135409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atmospheric oxygen breathing)
Number of subjects: 0
Study 31015098 — intervention group
Group type: EXPERIMENTAL
Intervention: MA + SSRIs
Number of subjects: 477
Study 31015098 — intervention group
Group type: EXPERIMENTAL
Intervention: EA + SSRIs
Number of subjects: 477
Study 29056453 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) auditory training for 8 weeks
Number of subjects: 0
Study 29056453 — intervention group
Group type: COMPARATOR
Intervention: Auditory working-memory (WM) task
Number of subjects: 0
Study 25168164 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise addition (SWA) of bolus insulin aspart
Number of subjects: 77000
Study 25168164 — intervention group
Group type: COMPARATOR
Intervention: Full basal-bolus (FBB) therapy
Number of subjects: 77000
Study 22313171 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones and berberine (ISB)
Number of subjects: 120
Study 22313171 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D(3) (CaD)
Number of subjects: 120
Study 20478551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular glucocorticoid injection
Number of subjects: 32
Study 20478551 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 32
Study 18400058 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 1177
Study 18400058 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 1177
Study 15977084 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transcatheter closure of PFO
Number of subjects: 24
Study 15977084 — intervention group
Group type: COMPARATOR
Intervention: Antimigraine drugs
Number of subjects: 24
Study 12464139 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (Ach)
Number of subjects: 11
Study 12464139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 11
Study 10480508 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 194
Study 10480508 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing quartiles of waist circumference
Number of subjects: 194
Study 10480508 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference in diabetic group
Number of subjects: 194
Study 10480508 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 194
Study 7702137 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy
Number of subjects: 35
Study 7702137 — intervention group
Group type: COMPARATOR
Intervention: Blind oral intubation
Number of subjects: 35
Study 7702137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 2746493 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose lorazepam (0.0225 mg/kg)
Number of subjects: 6
Study 2746493 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose lorazepam (0.045 mg/kg)
Number of subjects: 6
Study 2746493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2746493 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 6
Study 901139 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 0
Study 901139 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30957443 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxue Sanfeng acupuncture
Number of subjects: 70
Study 30957443 — intervention group
Group type: COMPARATOR
Intervention: Xingnao Kaiqiao acupuncture + nifedipine
Number of subjects: 70
Study 28816735 — intervention group
Group type: EXPERIMENTAL
Intervention: Short, frequent breaks (SBs)
Number of subjects: 49
Study 28816735 — intervention group
Group type: COMPARATOR
Intervention: Longer, planned breaks (LBs)
Number of subjects: 49
Study 26003804 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) followed by routine adjuvant systemic chemotherapy
Number of subjects: 176
Study 26003804 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy only
Number of subjects: 176
Study 23172931 — intervention group
Group type: COMPARATOR
Intervention: AM dose (once-daily antihypertensive medications taken in the morning)
Number of subjects: 147
Study 23172931 — intervention group
Group type: EXPERIMENTAL
Intervention: PM dose (once-daily antihypertensives taken at bedtime)
Number of subjects: 147
Study 23172931 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on dose (once-daily antihypertensives taken in the morning and an additional antihypertensive medication before bedtime)
Number of subjects: 147
Study 21816199 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg VLP vaccine
Number of subjects: 4563
Study 21816199 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 μg VLP vaccine
Number of subjects: 4563
Study 21816199 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg VLP vaccine
Number of subjects: 4563
Study 21816199 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4563
Study 19366957 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 18
Study 16690579 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of daily living skills using the Health Assessment Questionnaire (HAQ)
Number of subjects: 30
Study 16690579 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based test using the Assessment of Motor and Process Skills (AMPS)
Number of subjects: 30
Study 16690579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive status in participants with SLE
Number of subjects: 30
Study 16690579 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease severity in participants with SLE
Number of subjects: 30
Study 16690579 — intervention group
Group type: EXPERIMENTAL
Intervention: HAQ scores
Number of subjects: 30
Study 15454063 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 1192
Study 11550740 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 80
Study 11550740 — intervention group
Group type: COMPARATOR
Intervention: Behavioral treatment (BT)
Number of subjects: 80
Study 11550740 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention training (RPT)
Number of subjects: 80
Study 9024439 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for intervention clinic staff based on National Asthma Education and Prevention Program guidelines
Number of subjects: 22
Study 8102918 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 20
Study 8102918 — intervention group
Group type: COMPARATOR
Intervention: salbutamol
Number of subjects: 20
Study 2868074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 339
Study 2868074 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus cyclophosphamide (AC)
Number of subjects: 339
Study 2868074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus Doxorubicin and Cyclophosphamide (TAM plus AC)
Number of subjects: 339
Study 2868074 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM followed by AC
Number of subjects: 339
Study 2868074 — intervention group
Group type: EXPERIMENTAL
Intervention: AC followed by TAM
Number of subjects: 339
Study 2868074 — intervention group
Group type: COMPARATOR
Intervention: All three arms (TAM, AC, TAM plus AC)
Number of subjects: 339
Study 31350111 — intervention group
Group type: EXPERIMENTAL
Intervention: Speakers with PD
Number of subjects: 44
Study 31350111 — intervention group
Group type: COMPARATOR
Intervention: HOA speakers
Number of subjects: 44
Study 30074671 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby-led weaning (BLW)
Number of subjects: 280
Study 30074671 — intervention group
Group type: COMPARATOR
Intervention: Traditional spoon feeding (TSF)
Number of subjects: 280
Study 27908191 — intervention group
Group type: COMPARATOR
Intervention: Display window width of 100 HU
Number of subjects: 6
Study 27908191 — intervention group
Group type: EXPERIMENTAL
Intervention: Display window width of 40 HU
Number of subjects: 6
Study 25519029 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) administration
Number of subjects: 2
Study 22440535 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements and telemedical monitoring with daily assessment of body weight, number of taken oral energy supplements and state of health
Number of subjects: 26
Study 22440535 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study 20025554 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide (initial dose 7.5 - 15 mg titrated to 30 mg daily) + voglibose (0.9 mg daily)
Number of subjects: 36
Study 20025554 — intervention group
Group type: COMPARATOR
Intervention: Voglibose (0.9 mg daily)
Number of subjects: 36
Study 18217904 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 98
Study 18217904 — intervention group
Group type: COMPARATOR
Intervention: rATG
Number of subjects: 98
Study 15946554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy and postoperative therapy using lamivudine plus thymosin alpha1
Number of subjects: 33
Study 15946554 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy only
Number of subjects: 33
Study 12742477 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus with low-dose Prograf
Number of subjects: 0
Study 12742477 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus in calcineurin-free protocols
Number of subjects: 0